open access publication

Article, 2024

High-Sensitivity C-Reactive Protein Is Associated With Heart Failure Hospitalization in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease and Normal Left Ventricular Ejection Fraction Undergoing Coronary Angiography

Journal of the American Heart Association, ISSN 2047-9980, Volume 13, 3, 10.1161/JAHA.123.032997

Contributors

Zhou X.-D. 0000-0002-8534-0818 [1] Chen Q.-F. 0000-0001-6596-5004 [1] [2] Targher G. 0000-0002-4325-3900 [3] Byrne C.D. 0000-0001-6322-7753 [4] Shapiro M.D. 0000-0002-9071-3287 [5] Tian N. 0009-0007-3543-8036 [1] Xiao T. 0009-0007-5630-8759 [1] Sung K.-C. Lip G.Y.H. 0000-0002-7566-1626 [6] [7] Zheng M.-H. 0000-0003-4984-2631 (Corresponding author) [1] [2] [8]

Affiliations

  1. [1] The First Affiliated Hospital of Wenzhou Medical University
  2. [NORA names: China; Asia, East];
  3. [2] Wenzhou Medical University
  4. [NORA names: China; Asia, East];
  5. [3] University of Verona
  6. [NORA names: Italy; Europe, EU; OECD];
  7. [4] Southampton General Hospital
  8. [NORA names: United Kingdom; Europe, Non-EU; OECD];
  9. [5] Wake Forest School of Medicine
  10. [NORA names: United States; America, North; OECD];

Abstract

BACKGROUND: Systemic chronic inflammation plays a role in the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated fatty liver disease. This study aimed to investigate whether serum hs-CRP (high-sensitivity C-reactive protein) levels were associated with the future risk of heart failure (HF) hospitalization in patients with metabolic dysfunction-associated fatty liver disease and a normal left ventricular ejection fraction. METHODS AND RESULTS: The study enrolled consecutive individuals with metabolic dysfunction-associated fatty liver disease and normal left ventricular ejection fraction who underwent coronary angiography for suspected coronary heart disease. The study population was subdivided into non-HF, pre-HFpEF, and HFpEF groups at baseline. The study outcome was time to the first hospitalization for HF. In 10 019 middle-aged individuals (mean age, 63.3±10.6 years; 38.5% women), the prevalence rates of HFpEF and pre-HFpEF were 34.2% and 34.5%, with a median serum hs-CRP level of 4.5 mg/L (interquartile range, 1.9–10 mg/L) and 5.0 mg/L (interquartile range, 2.1–10.1 mg/L), respectively. Serum hs-CRP levels were significantly higher in the pre-HFpEF and HFpEF groups than in the non-HF group. HF hospitalizations occurred in 1942 (19.4%) patients over a median of 3.2 years, with rates of 3.7% in non-HF, 20.8% in pre-HFpEF, and 32.1% in HFpEF, respectively. Cox regression analyses showed that patients in the highest hs-CRP quartile had a ≈4.5-fold increased risk of being hospitalized for HF compared with those in the lowest hs-CRP quartile (adjusted-hazard ratio, 4.42 [95% CI, 3.72–5.25]). CONCLUSIONS: There was a high prevalence of baseline pre-HFpEF and HFpEF in patients with metabolic dysfunction-associated fatty liver disease and suspected coronary heart disease. There was an increased risk of HF hospitalization in those with elevated hs-CRP levels.

Keywords

heart failure hospitalization, heart failure with preserved ejection fraction, high-sensitivity C-reactive protein, metabolic dysfunction-associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease

Funders

  • National Institute for Health Research Southampton Biomedical Research Centre
  • Horizon 2020 Framework Programme
  • School of Medicine, University of Virginia
  • National Institute for Health and Care
  • Department of Public Health in Zhejiang Province
  • National Natural Science Foundation of China

Data Provider: Elsevier